In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 6.02 below Spero Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 166 other companies have achieved higher Quick Ratio than Spero Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 322 to 631.

Explain Quick Ratio?
How much Cash & cash equivalents SPRO�s has?
What are SPRO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SPRO Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-43.61 %	-81.17 %	-81.93 %	-72.2 %	-67.25 %
Y / Y Cash & cash equivalent Change	62.77 %	14.81 %	-23.87 %	-36.27 %	-50.9 %
Quick Ratio MRQ	6.02	10.23	4.54	3.56	2.09
SPRO's Total Ranking	# 631	# 322	# 650	# 649	# 885
Seq. Current Liabilities Change	53.54 %	-38.1 %	-35.03 %	-8.67 %	-48.74 %
Seq. Cash & cash equivalent Change	-9.54 %	39.4 %	-17.18 %	55.85 %	-36.19 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 167
Healthcare Sector	# 264
Overall Market	# 631

Quick Ratio Statistics
High	Average	Low
76.56	7.59	0.74
(Sep 30 2018)		(Sep 30 2014)

Financial Statements
Spero Therapeutics Inc 's Current Liabilities	$ 8 Millions	Visit SPRO's Balance sheet
Spero Therapeutics Inc 's Cash & cash equivalent	$ 51 Millions	Visit SPRO's Balance sheet
Source of SPRO's Sales		Visit SPRO's Sales by Geography

Cumulative Spero Therapeutics Inc 's Quick Ratio

SPRO's Quick Ratio for the trailling 12 Months

SPRO Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-74.39 %	-75.17 %	-64.11 %	-38.5 %	-5.2 %
Y / Y Cash & cash equivalent TTM Growth	-6.44 %	-27.07 %	-38.55 %	-39.15 %	-33.77 %
Quick Ratio TTM	5.37	4.1	2.54	1.7	1.47
Total Ranking TTM	# 3654	# 3690	# 2980	# 3141	# 2689
Seq. Current Liabilities TTM Growth	-15.17 %	-35.53 %	-37.64 %	-24.92 %	-17.74 %
Seq. Cash & cash equivalent TTM Growth	11.11 %	4.29 %	-6.95 %	-13.22 %	-13.38 %

Quick ratio ranking by company, industry and sector >> Back to SPRO Financial Strength Comparisons >> Go to Compare SPRO Quick Ratio to its Competitors

News about Spero Therapeutics Inc Quick Ratio

Spero Therapeutics Announces Inducement Grant and Improved Financial Performance

Spero Therapeutics, Inc. recently announced the approval of 116,667 restricted stock unit awards to a new employee as an inducement under the 2019 Inducement Equity Incentive Plan. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company s focus on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial infections.
Additionally, Spero Therapeutics saw a significant improvement in its financial performance, with a surge in cash and cash equivalents by 85.99% in the third quarter of 2023 compared to the previous year. Despite an increase in current liabilities affecting the Quick Ratio, the trailing twelve months Quick Ratio rose to 4.31, exceeding the company s average.

Spero Therapeutics Empowers New Employee with Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2024 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a pioneering biopharmaceutical company specializing in the development of groundbreaking treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, revealed today that it has undertaken a momentous step in its journey. On April 29, 2024, the Compensation Committee of Spero s Board of Directors authorized the issuance of 10,833 restricted stock unit awards (RSUs) to a newly hired employee. This action aligns with the provisions outlined in the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, commonly referred to as the 2019 Inducement Plan. With this development deemed critical in acquiring the services of the new employee under Nasdaq Listing Rule 5635(c)(4), Spero opens a new chapter in its commitment to achieve groundbreaking medical milestones.
The granting of these RSUs reflects Spero Therapeutics dedication to attracting and retaining top talent within its organization. As a clinical-stage biopharmaceutical company, Spero understands that its ultimate success in addressing rare diseases and combating MDR bacterial infections lies in the hands of its highly skilled team members. By leveraging the 2019 Inducement Plan, Spero can incentivize new employees and solidify long-term commitment from the best in the industry.

On the trailing twelve months basis SPRO Cash & cash equivalent soared by 62.77 % in Q2 2026 year on year, while Current Liabilities soared to $8 millions, this led to increase in in Spero Therapeutics Inc 's Quick Ratio to 5.37, above SPRO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 424 other companies have achieved higher Quick Ratio than Spero Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3654, from total ranking during the twelve months ending first quarter 2026 at 3690.

Explain Quick Ratio?
How much Cash & cash equivalents SPRO�s has?
What are SPRO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 425
Healthcare Sector	# 865
Within the Market	# 3654

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.18	3.61	0.78
(Jun 30 2019)		(Dec 31 2014)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Olema Pharmaceuticals Inc	16.48	$ 873.571 Millions	$ 53.014 Millions
Erasca Inc	16.41	$ 610.496 Millions	$ 37.200 Millions
Janux Therapeutics Inc	16.14	$ 970.913 Millions	$ 60.152 Millions
Edgewise Therapeutics inc	15.86	$ 460.709 Millions	$ 29.042 Millions
Corvus Pharmaceuticals Inc	15.74	$ 215.200 Millions	$ 13.672 Millions
Telomir Pharmaceuticals Inc	15.55	$ 5.170 Millions	$ 0.332 Millions
Rapport Therapeutics Inc	15.34	$ 436.077 Millions	$ 28.424 Millions
Lb Pharmaceuticals Inc	15.32	$ 369.576 Millions	$ 24.128 Millions
Anixa Biosciences Inc	15.09	$ 26.330 Millions	$ 1.745 Millions
Siga Technologies Inc	14.99	$ 117.584 Millions	$ 7.845 Millions
Vyne Therapeutics Inc	14.87	$ 22.925 Millions	$ 1.542 Millions
Alto Neuroscience Inc	14.64	$ 243.733 Millions	$ 16.652 Millions
Tenax Therapeutics Inc	14.62	$ 118.000 Millions	$ 8.073 Millions
Jade Biosciences Inc	14.61	$ 461.205 Millions	$ 31.570 Millions
Immunome Inc	14.56	$ 519.996 Millions	$ 35.713 Millions
Sensei Biotherapeutics Inc	14.54	$ 186.441 Millions	$ 12.824 Millions
Cytokinetics Incorporated	14.39	$ 2,610.415 Millions	$ 181.429 Millions
Canton Strategic Holdings Inc	14.18	$ 37.242 Millions	$ 2.626 Millions
An2 Therapeutics Inc	14.04	$ 78.387 Millions	$ 5.585 Millions
Aclaris Therapeutics Inc	13.97	$ 394.443 Millions	$ 28.241 Millions
Pmv Pharmaceuticals Inc	13.85	$ 146.393 Millions	$ 10.568 Millions
Generate Biomedicines Inc	13.76	$ 779.456 Millions	$ 56.636 Millions
First Tracks Biotherapeutics Inc	13.50	$ 168.018 Millions	$ 12.447 Millions
Arrivent Biopharma inc	13.41	$ 373.401 Millions	$ 27.844 Millions
Cogent Biosciences Inc	13.36	$ 792.300 Millions	$ 59.296 Millions
Aprea Therapeutics Inc	13.33	$ 41.233 Millions	$ 3.092 Millions
Polaryx Therapeutics Inc	13.22	$ 11.542 Millions	$ 0.873 Millions
Monopar Therapeutics Inc	13.14	$ 52.758 Millions	$ 4.016 Millions
Lexicon Pharmaceuticals Inc	12.96	$ 190.610 Millions	$ 14.706 Millions
Korro Bio Inc	12.89	$ 162.805 Millions	$ 12.628 Millions

Date modified: 2026-09-26T07:32:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.